Applied DNA Sciences, Inc. Stock price

Equities

APDN

US03815U3005

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.41 USD -4.21% Intraday chart for Applied DNA Sciences, Inc. -18.00% -33.53%
Sales 2024 * 5.02M Sales 2025 * 8.17M Capitalization 6.96M
Net income 2024 * -12M Net income 2025 * -13M EV / Sales 2024 * 1.39 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.85 x
P/E ratio 2024 *
-0.63 x
P/E ratio 2025 *
-0.77 x
Employees 54
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.36%
More Fundamentals * Assessed data
Dynamic Chart
Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress CI
Applied DNA Sciences Files Prospectus for Potential Secondary Stock Offerings MT
Transcript : Applied DNA Sciences, Inc., Q1 2024 Earnings Call, Feb 08, 2024
Earnings Flash (APDN) APPLIED DNA SCIENCES Reports Q1 Revenue $891,164 MT
Applied DNA Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Applied DNA Sciences, Inc. Announces Joint Development Agreement to Integrate Linea IVT Platform into CDMO Kudo Biotechnology?s mRNA Manufacturing Workflow CI
HC Wainwright Cuts Price Target on Applied DNA Sciences to $2 From $4, Keeps Buy Rating MT
Transcript : Applied DNA Sciences, Inc., Q4 2023 Earnings Call, Dec 07, 2023
Earnings Flash (APDN) APPLIED DNA SCIENCES Posts Q4 Revenue $779,736, vs. Street Est of $1.7M MT
Applied DNA Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023 CI
Applied DNA Sciences, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Applied DNA Sciences, Inc. Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application CI
Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna) CI
Applied DNA Sciences, Inc. Advances Commercialization of Linea(TM) IVT Platform CI
Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs CI
More news
1 day-4.21%
1 week-18.00%
Current month-29.47%
1 month-31.21%
3 months-35.94%
6 months-65.83%
Current year-33.53%
More quotes
1 week
0.41
Extreme 0.41
0.50
1 month
0.37
Extreme 0.368
0.60
Current year
0.37
Extreme 0.368
0.72
1 year
0.37
Extreme 0.368
1.86
3 years
0.37
Extreme 0.368
9.96
5 years
0.37
Extreme 0.368
33.60
10 years
0.37
Extreme 0.368
388.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 71 05-09-27
Director of Finance/CFO 47 13-04-30
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 74 06-03-16
Director/Board Member 87 16-10-06
Chief Executive Officer 71 05-09-27
More insiders
Date Price Change Volume
24-03-28 0.41 -4.21% 50,495
24-03-27 0.428 -1.77% 62,574
24-03-26 0.4357 -9.23% 81,413
24-03-25 0.48 -3.81% 57,984
24-03-22 0.499 -0.20% 95,784

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company's proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. It also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company's Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.41 USD
Average target price
2.25 USD
Spread / Average Target
+448.78%
Consensus
  1. Stock
  2. Equities
  3. Stock Applied DNA Sciences, Inc. - Nasdaq